Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19) https://doi.org/10.1016/j.cmi.2020.08.010 A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 with clinical and laboratory data indicative of hyperinflammatory state.… Continue reading "(30 Aug 2020) Tocilizumab- associated with lower hazard of death"
Tocilizumab use in COVID -19 associated pneumonia https://doi.org/10.1002/jmv.26471 Out of 77 patients who received TCB in addition to standard of care, 34% (n=26) received TCB within 48 hours of admission. One-to-two propensity matching identified 20 vs. 40 patients in the… Continue reading "(30 August 2020) Tocilizumab- improvement in oxygenation was observed in 80% (n=16) of the patients by7 days"
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study https://doi.org/10.1016/j.ejim.2020.08.019 In a retrospective observational study, 3,451 unselected patients hospitalized in 33 clinical centers in Italy. Out of 3,451 COVID-19… Continue reading "(30 Aug 2020) Hydroxychloroquine- associated with a 30% lower risk of death in COVID-19 hospitalized patients"
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19 https://doi.org/10.14309/ajg.0000000000000832 Of 878 patients in the analysis, 83 (9.5%) received famotidine. In comparison to patients not treated with famotidine, patients treated with famotidine were younger (63.5 +/- 15.0… Continue reading "(28 Aug 2020) Famotidine- associated with a lower risk of mortality"
Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants https://doi.org/10.1016/j.ijantimicag.2020.106144 Of 8075 patients with complete discharge data on 24(th) of May and diagnosed before the 1(st) of May, 4542 received HCQ in… Continue reading "(28 Aug 2020) Hydroxychloroquine- low-dose HCQ monotherapy was independently associated with lower mortality in hospitalized patients"
Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients https://doi.org/10.3389/fphar.2020.01124 The in-hospital mortality between COVID-19 patients treated with standard prophylactic LMWH dosage vs. intermediate LMWH dosage was compared in a retrospective study. Out of 450 patients, 361 received… Continue reading "(28 Aug 2020) LMW Heparin-associated with lower incidence of mortality"
Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol https://doi.org/10.3389/fmed.2020.00466 Data collection shows a rapid clinical response with no evolution from non-invasive ventilation to mechanical ventilation in 16/18 patients and no response in… Continue reading "(28 Aug 2020) Ruxolinitib- after 48 h of ruxolitinib treatment 16/18 patients showed evident clinical improvement"
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study https://www.medrxiv.org/content/10.1101/2020.08.20.20178772v1.full.pdf Among 1274 outpatients with documented SARS-CoV-2 infection 7.6% were prescribed hydroxychloroquine. In a 1067 patient propensity matched cohort, 21.6% with outpatient exposure to hydroxychloroquine were… Continue reading "(25 Aug 2020) Hydroxychloroquine- associated with a decreased rate of subsequent hospitalization"
Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU https://doi.org/10.1093/jac/dkaa321 A total of 51 patients were considered, of which 25 were treated with remdesivir. The median (IQR) age was 67 (59-75.5) years, 92% were men… Continue reading "(24 Aug 2020) Remdesivir-associated with better survival"
Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study https://doi.org/10.4269/ajtmh.20-0873 This was a multicenter, randomized controlled trial conducted at three major university hospitals in Egypt. One hundred ninety-four patients with confirmed diagnosis of COVID-19 were included in the… Continue reading "(24 Aug 2020) Hydroxychloroquine- No significant benefit observed"
